What question did this study set out to answer?

To streamline the characterization of antibody effector functions using innovative assays for therapeutic development.

April 5, 2026

Abstract 1652: Binding to bridging: Complete suite of FcγR assay tools accelerates antibody therapeutic development

Key Points

To streamline the characterization of antibody effector functions using innovative assays for therapeutic development.
Developed luminescent assays including Lumit® Binding Immunoassays and Fc Effector Reporter Bioassays.
Applied assays to characterize anti-CD20 biosimilar antibodies for effectiveness in immune response.
Ensured use of MoA-qualified primary cells for accurate functional measurements.
Demonstrated concordant rank order from binding to functional killing studies.
Assays supported comparability, stability, and lot-release decisions efficiently.
High-throughput capabilities significantly reduced time and variability in measurements.

Abstract

Abstract Antibodies are effective therapeutics because of their specificity in binding to an antigen and ability to activate an immune response through Fc effector functions like antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC) by engaging with immune cells like NK cells and macrophage. However, traditional methods for characterizing these interactions are highly variable and labor-intensive. We developed a suite of luminescent assays for characterizing antibody effector functions for robust, streamlined measurement across antibody development: Lumit® Binding Immunoassays, Fc Effector Reporter Bioassays for ADCC/ADCP, and HiBiT Target Cell Killing Bioassays using MoA-qualified primary cells. We demonstrate application to anti-CD20 biosimilar antibodies, showing concordant rank order from binding to functional killing studies. These rapid, high-throughput assays support comparability, stability, and lot-release decisions. Citation Format: Julia K. Gilden, Denise Garvin, Kristin Riching, Brock F. Binkowski, Richard Moravec, Pete Stecha, Rod Flemming, Becky Godat, Kai Hillman, Marjeta Urh, Mei Cong, Jamison Grailer, . Binding to bridging: Complete suite of FcγR assay tools accelerates antibody therapeutic development abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1652.

KI fragen

Bookmark